Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...
The Manila Times

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in ...

Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells ...
The Manila Times

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea” or the "Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it has ...
Nasdaq

Monte Rosa Therapeutics Begins Phase 1 Study of MRT-8102 for Inflammatory Conditions with Initial Results Expected in H1 2026

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.
The American Journal of Managed Care

Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC

Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...